Tango Therapeutics, Inc. (TNGX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$160.0M
Cash & Equivalents
$44.4M
Quarterly Burn Rate
11 mo
Est. Cash Runway
$2,842M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06188702 | S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletio... | PHASE2 | Active Not Recruiting | 60 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.